KIMBERLY KELLEY: Open Payments
NPI 1750032645 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,169 in 188 payments from 13 companies in 2025. Trend: 2023 $2,161 · 2024 $2,852 · 2025 $4,169
Food & beverage: $4,057Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 32 | $700 |
| Neurocrine BioSciences, Inc. | 21 | $530 |
| Otsuka America Pharmaceutical, Inc. | 23 | $485 |
| Alkermes, Inc. | 18 | $425 |
| E.R. Squibb & Sons, L.L.C. | 23 | $370 |
| Vanda Pharmaceuticals Inc. | 17 | $350 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $308 |
| Axsome Therapeutics, Inc. | 5 | $273 |
| Janssen Pharmaceuticals, Inc | 12 | $262 |
| Lundbeck LLC | 20 | $230 |
Products named: INGREZZA, UZEDY, COBENFY, FANAPT, ABILIFY MAINTENA, CAPLYTA, ARISTADA, Auvelity.
Industry payments across MS — which companies pay providers there.
